|  | 
| MechanismCLL-1 inhibitors | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePhase 1/2 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
| Mechanism- | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
| Mechanism- | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
 / Not yet recruitingNot Applicable A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies
This study will evaluate the long-term safety of ARD103 cellular therapies
100 Clinical Results associated with Arce Therapeutics, Inc.
0  Patents (Medical) associated with Arce Therapeutics, Inc.
100 Deals associated with Arce Therapeutics, Inc.
100 Translational Medicine associated with Arce Therapeutics, Inc.